Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Go back to Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine| (NASDAQ: PRAX) | Delayed: 298.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $298.95 | 52 Week High | $ | |||
| Open | $298.95 | 52 Week Low | $ | |||
| Day High | $298.95 | P/E | N/A | |||
| Day Low | $298.95 | EPS | $ | |||
| Volume | 34 | |||||
